Clinical trial

Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study

Thursday, July 29, 2021 - 3:05pm

The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.

Key Points: 
  • The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
  • In the pilot animal study, an adult version of Sigyn Therapywas administered to two porcine (pig) subjects (each ~ 40 kilos) to evaluate the feasibility of a therapeutic protocol designed to support subsequent clinical studies.In the study, Sigyn Therapy was deployed on a standard dialysis hardware system and utilized conventional blood-tubing set configurations.
  • Craig Roberts, Chief Technical Officer at Sigyn Therapeutics, added, We are pleased with the results of our pilot study, which provides us with clinical evidence that our device can be safely used without complications or adverse events.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Global Atrial Fibrillation Clinical Trials Review Report - H1, 2021 - ResearchAndMarkets.com

Friday, July 30, 2021 - 12:46pm

The "Atrial Fibrillation - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atrial Fibrillation - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Atrial Fibrillation Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Atrial Fibrillation.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Immuno-oncology Clinical Trials Market Research Report 2021: Analysis by Phase (Phase I, Phase II, Phase III, Phase IV), Design (Interventional Trials, Observational Trials), & Indication - ResearchAndMarkets.com

Thursday, July 29, 2021 - 5:06pm

The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028.
  • The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.
  • At the end of 2019, over 40.0% of current immuno-oncology clinical experiments involved at least one location in the region
    Chapter 3 Immuno-oncology clinical trials Market: Variables, Trends, & Scope
    Chapter 4 Immuno-oncology Clinical Trials Market: Phase Segment Analysis
    4.1 Immuno-oncology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Thursday, July 29, 2021 - 12:31pm

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

Global Graves' Ophthalmopathy Disease Clinical Trials Review: H1, 2021 - ResearchAndMarkets.com

Thursday, July 29, 2021 - 11:10am

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

Key Points: 
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level

Real Chemistry’s IPM.ai Accelerates the Clinical Investigation and Commercialization of Life-Saving Precision Medicines by Applying AI and ML to Real-World Data

Thursday, July 29, 2021 - 2:00pm

Life science customers can use The Real Chemistry Clinical Trial Recruitment System to efficiently and effectively find medically-eligible patients within their healthcare ecosystems.

Key Points: 
  • Life science customers can use The Real Chemistry Clinical Trial Recruitment System to efficiently and effectively find medically-eligible patients within their healthcare ecosystems.
  • This technology-based approach is designed to accelerate clinical investigations and lead to faster patient outcomes with less risk.
  • "With 90% of clinical evaluations for rare diseases failing to meet patient recruitment goals, a new approach is needed," said IPM.ai Co-Founder and President Ron Elwell.
  • The traditional strategies used for high prevalence, highly diagnosed diseases have proven ineffective for uncommon conditions, which is why our transformative approach rewrites the clinical recruitment playbook for specialty medicines.

Axcella Reports Second Quarter Financial Results and Provides Business Update

Thursday, July 29, 2021 - 12:28pm

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
  • As we enter the second half of 2021, maximizing clinical trial enrollment and expanding Axcellas pipeline are our primary areas of focus.
  • Axcella continues to expect that its existing cash balance will be sufficient to meet the companys operating needs into the third quarter of 2022.
  • ET to discuss the companys financial results and other recent business updates.

Eisai presented latest data from the lecanemab clinical program at AAIC 2021

Friday, July 30, 2021 - 7:13am

The presentations included the latest data for the investigational anti-amyloid beta antibody lecanemab (BAN2401), for which the FDA recently granted Breakthrough Therapy designation.

Key Points: 
  • The presentations included the latest data for the investigational anti-amyloid beta antibody lecanemab (BAN2401), for which the FDA recently granted Breakthrough Therapy designation.
  • In an oral presentation, baseline characteristics and results from the preliminary screening of the Phase 3 clinical study, AHEAD 3-45, for preclinical (asymptomatic) Alzheimer's disease, were presented.
  • For the first time, clinical outcome data from a small cohort of the large Phase 2b open label extension study were presented.
  • "It's very encouraging to see that Eisai's broad clinical program for lecanemab continues to deliver data in support of the effects on both amyloid in the brain and cognitive outcomes.

Eisai presented latest data from the lecanemab clinical program at AAIC 2021

Friday, July 30, 2021 - 7:11am

The presentations included the latest data for the investigational anti-amyloid beta antibody lecanemab (BAN2401), for which the FDA recently granted Breakthrough Therapy designation.

Key Points: 
  • The presentations included the latest data for the investigational anti-amyloid beta antibody lecanemab (BAN2401), for which the FDA recently granted Breakthrough Therapy designation.
  • In an oral presentation, baseline characteristics and results from the preliminary screening of the Phase 3 clinical study, AHEAD 3-45, for preclinical (asymptomatic) Alzheimer's disease, were presented.
  • For the first time, clinical outcome data from a small cohort of the large Phase 2b open label extension study were presented.
  • "It's very encouraging to see that Eisai's broad clinical program for lecanemab continues to deliver data in support of the effects on both amyloid in the brain and cognitive outcomes.

Global Dental Pain (Toothache Tooth Pain) Clinical Trials Review, H2 2021 Research Report - ResearchAndMarkets.com

Thursday, July 29, 2021 - 8:53am

The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" provides an overview of the Dental Pain (Toothache Tooth Pain) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Dental Pain (Toothache Tooth Pain).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials